Welcome to our dedicated page for Xenon Pharmaceuticals SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
Xenon Pharmaceuticals Inc. (XENE) director Dawn Svoronos exercised stock options for 5,144 Common Shares on September 1, 2026 at an exercise price of $8.15 per share, converting fully vested options into shares. Following the exercise, she holds 31,373 Common Shares directly, and no related Rule 10b5-1 trading plan is reported.
Xenon Pharmaceuticals Inc. (XENE) reported that Chief Medical Officer Christopher John Kenney sold a total of 7,068 Common Shares on August 28, 2026 in two open-market transactions, executed under a Rule 10b5-1 trading plan adopted on May 29, 2026. The reported prices are weighted-average prices for multiple trades within specified intraday ranges.
Xenon Pharmaceuticals Inc. (XENE) had an officer, Christopher Kenney, file a notice of proposed sale of company stock under Rule 144. The notice covers up to 7,068 common shares, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $437,721.24 and listing on NASDAQ. The shares are to be sold on or after 08/28/2026 and were acquired upon vesting of restricted and performance stock units from Xenon on 03/09/2026 and 03/12/2026.
Xenon Pharmaceuticals Inc. director Steven Gannon reported selling 10,000 Common Shares on August 11, 2026 in an open market or private transaction. The shares were sold at a weighted-average price of $64.055 across multiple trades priced between $64.0517 and $64.078 per share. Following this sale, Gannon directly holds 1,870 Common Shares of Xenon Pharmaceuticals Inc.
A holder of XENE common shares filed a notice of intention to sell 10,000 common shares through RBC Wealth Management, 1501 Ave. McGill College, Suite 2150, Montreal, with the shares listed on NASDAQ. The proposed sale date is 08/11/2026.
The disclosure also lists past transactions in common shares: an Open Market Purchase of 15,000 shares on 08/11/2017, an Exercise of Options with the issuer for 5,144 shares on 05/14/2025, and another Exercise of Options for 3,500 shares on 05/12/2026, each settled in cash.
Wellington Management Group LLP and affiliates report a passive ownership position in Xenon Pharmaceuticals Inc. common stock. The filing shows aggregate beneficial ownership of approximately 1.47% of the outstanding common shares, representing shares held for clients of various Wellington investment adviser entities.
The Wellington entities report no sole voting or dispositive power, with all reported voting and dispositive authority held on a shared basis across group entities. The securities are owned of record by advisory clients, and no individual client is reported to hold more than five percent of the class.
FMR LLC filed Amendment No. 8 to a Schedule 13G reporting its beneficial ownership of common stock of Xenon Pharmaceuticals Inc. FMR LLC reports beneficial ownership of 9,959,795.17 shares of common stock, representing 10.3% of the class. It reports sole voting power over 9,951,732.00 shares and sole dispositive power over 9,959,795.17 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 9,959,795.17 shares and no voting power. The filing notes that one or more other persons may have rights to receive dividends or sale proceeds from these securities, but no such person has an interest exceeding five percent of Xenon’s outstanding common stock.
Xenon Pharmaceuticals Inc. reported second-quarter 2026 results marked by higher operating losses as it advances late-stage neurology programs. For the quarter, net loss was $110.7 million, and for the first half of 2026 net loss totaled $213.0 million, with no collaboration revenue versus $7.5 million a year earlier.
Research and development expense rose to $99.2 million in Q2 and $187.7 million for the first half, driven mainly by Phase 3 studies of azetukalner in epilepsy and mood disorders and early-stage pain programs. General and administrative expense reached $47.8 million for the half. Cash, cash equivalents and marketable securities were $1.25 billion as of June 30, 2026, bolstered by an $130.0 million ATM issuance and a $707.6 million underwritten equity and pre-funded warrant offering. Management states this liquidity is expected to fund operations for at least 12 months. The company plans to submit an NDA for azetukalner in focal onset seizures in the third quarter of 2026 and continues multiple Phase 3 and Phase 1 trials across epilepsy, depression and pain.
Xenon Pharmaceuticals reported Q2 2026 results alongside significant clinical and regulatory progress for its lead KV7 modulator azetukalner. After a successful pre-NDA meeting with the FDA, the company plans to submit a New Drug Application for azetukalner in focal onset seizures in the third quarter of 2026. Phase 3 trials continue across epilepsy (X-TOLE3, X-ACKT), major depressive disorder (X-NOVA2 and X-NOVA3) and bipolar depression (X-CEED), with topline X-NOVA2 data anticipated in the first half of 2027.
Cash, cash equivalents and marketable securities totaled $1,245.1 million as of June 30, 2026, compared with $586.0 million as of December 31, 2025, and management expects this to fund operations into 2029. For Q2 2026, Xenon reported a net loss of $110.7 million and no revenue, versus a $84.7 million net loss in Q2 2025, as research and development expenses increased to $99.2 million and general and administrative expenses to $23.9 million, driven by late-stage azetukalner programs, pain studies, manufacturing, and higher personnel costs. Other income rose to $11.8 million, primarily from higher interest income, and 96,752,884 common shares and 2,931,293 pre-funded warrants were outstanding as of June 30, 2026.
FMR LLC reported its beneficial ownership of common stock of Xenon Pharmaceuticals Inc. as of June 30, 2026. FMR LLC beneficially owned 9,599,498 shares of common stock, representing 9.9% of the class, with sole dispositive power over all such shares and sole voting power over 9,591,437 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 9,599,498 shares and no voting power. The securities are held on behalf of underlying clients and other persons who have rights to dividends or sale proceeds, but no other single person has an interest in more than five percent of the outstanding common stock.